Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Gavish-Galilee Bio Applications Ltd. is active in the Biotechnology & Pharmaceuticals technology area, currently overseeing 3 pending office actions. These actions are spread across 3 distinct examiners and 3 distinct art units. This 1:1 ratio between actions, examiners, and art units suggests that each pending matter involves a unique technical focus or is being handled in a completely separate administrative silo. Such a structure requires the company to navigate three different sets of examiner preferences and art unit trends simultaneously.
The busiest examiner for this portfolio is SINGH, ANOOP KUMAR, who is currently managing 1 pending action. Given that there are 3 pending office actions in total and 3 distinct examiners, each examiner is responsible for exactly one case. This distribution highlights a lack of examiner overlap, which can lead to varied prosecution timelines and outcomes across the portfolio. Practitioners must prepare for diverse feedback across the 3 distinct art units involved in these proceedings. The outcome of the company's current patent efforts depends on the interactions within these three separate administrative channels and the standards of the Biotechnology & Pharmaceuticals division.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SINGH, ANOOP KUMAR | 1 | 43.0% | +67.6% |
| BERHANE, SELAM | 1 | 58.4% | +56.7% |
| HOLTZMAN, KATHERINE ANN | 1 | 65.7% | +58.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16586730 | METHODS FOR IDENTIFYING ACTIVATING ANTIGEN RECEPTOR (aCAR)/INHIBITORY CHIMERIC ANTIGEN RECEPTOR (iCAR) PAIRS FOR USE IN CANCER THERAPIES | HOLTZMAN, KATHERINE ANN | 6d |
| 17598208 | GENETICALLY REPROGRAMMED TREGS EXPRESSING CARS | SINGH, ANOOP KUMAR | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16586730 | METHODS FOR IDENTIFYING ACTIVATING ANTIGEN RECEPTOR (aCAR)/INHIBITORY CHIMERIC ANTIGEN RECEPTOR (iCAR) PAIRS FOR USE IN CANCER THERAPIES | HOLTZMAN, KATHERINE ANN | 6d |
| 17598208 | GENETICALLY REPROGRAMMED TREGS EXPRESSING CARS | SINGH, ANOOP KUMAR | — |
| 17040851 | GENETICALLY REPROGRAMMED TREGS EXPRESSING MEMBRANE-BOUND IL-10 | BERHANE, SELAM | — |
| Art Unit | Apps |
|---|---|
| 1632 | 1 |
| 1675 | 1 |
| 1646 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17598208 | GENETICALLY REPROGRAMMED TREGS EXPRESSING CARS | SINGH, ANOOP KUMAR | 1632 | §103§112 | Final Rejection | — | Pending | Sep 24, 2021 |
| 17040851 | GENETICALLY REPROGRAMMED TREGS EXPRESSING MEMBRANE-BOUND IL-10 | BERHANE, SELAM | 1675 | §112 | Final Rejection | — | Pending | Sep 23, 2020 |
| 16586730 | METHODS FOR IDENTIFYING ACTIVATING ANTIGEN RECEPTOR (aCAR)/INHIBITORY CHIMERIC ANTIGEN RECEPTOR (iCAR) PAIRS FOR USE IN CANCER THERAPIES | HOLTZMAN, KATHERINE ANN | 1646 | §103§112 | Final Rejection | 6d | Pending | Sep 27, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial